ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.20) by 15 percent. This is a 15 percent decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $10.400 million which beat the analyst consensus estimate of $10.050 million by 3.48 percent. This is a 33.83 percent increase over sales of $7.771 million the same period last year.